exosomes + azelastine + interferon alpha-2b

Exosomes + azelastine + interferon alpha-2b is an investigational, multi-component nasal spray formulation being developed by the First Affiliated Hospital of Xinxiang Medical College for the treatment of chronic rhinosinusitis (CRS) during acute phases. The drug is delivered as a thermosensitive gel that transitions into a soft gel upon contact with the nasal mucosa to provide sustained release of its three active components. These include: (1) umbilical cord mesenchymal stem cell (UC-MSC)-derived exosomes, which provide immunomodulatory and tissue-regenerative effects; (2) azelastine, a selective H1-receptor antagonist that reduces allergic inflammation and stabilizes mast cells; and (3) interferon alpha-2b, a recombinant cytokine that exerts antiviral and immunomodulatory actions. This combination therapy aims to repair the nasal lining, reduce inflammation, and combat viral triggers associated with acute exacerbations of CRS.

Other names

umbilical cord mesenchymal stem cell-derived exosomes + azelastine + interferon alpha-2bUC-MSC exosomes + azelastine + interferon alpha-2bExosomes, Azelastine, and Interferon alpha-2b Nasal Spray